Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Decreases By 32.3%

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) saw a large drop in short interest during the month of March. As of March 13th, there was short interest totaling 1,402,079 shares, a drop of 32.3% from the February 26th total of 2,069,809 shares. Based on an average trading volume of 497,946 shares, the days-to-cover ratio is currently 2.8 days. Approximately 3.8% of the shares of the company are short sold.

Insider Transactions at Werewolf Therapeutics

In other news, Director Luke Evnin sold 58,980 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $0.57, for a total value of $33,618.60. Following the completion of the transaction, the director directly owned 2,309,869 shares of the company’s stock, valued at $1,316,625.33. This trade represents a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders sold 499,420 shares of company stock valued at $296,825. Insiders own 23.60% of the company’s stock.

Institutional Trading of Werewolf Therapeutics

A number of hedge funds have recently bought and sold shares of HOWL. Regal Investment Advisors LLC grew its holdings in shares of Werewolf Therapeutics by 93.3% in the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after purchasing an additional 25,389 shares during the last quarter. Qube Research & Technologies Ltd bought a new stake in Werewolf Therapeutics during the 2nd quarter valued at $48,000. Susquehanna International Group LLP raised its holdings in Werewolf Therapeutics by 16.9% during the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after buying an additional 13,439 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Werewolf Therapeutics during the 3rd quarter valued at $304,000. Finally, Renaissance Technologies LLC grew its holdings in Werewolf Therapeutics by 48.6% in the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after acquiring an additional 221,766 shares during the last quarter. Institutional investors own 64.84% of the company’s stock.

Analysts Set New Price Targets

HOWL has been the subject of several recent analyst reports. Citigroup cut Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Friday, December 19th. HC Wainwright dropped their price target on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research report on Friday, December 19th. Citizens Jmp lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, December 19th. Wedbush cut shares of Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price objective on the stock. in a research report on Friday, December 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $3.75.

Werewolf Therapeutics Price Performance

HOWL traded down $0.08 during trading on Friday, reaching $0.78. The stock had a trading volume of 374,982 shares, compared to its average volume of 381,100. The stock has a market cap of $37.90 million, a PE ratio of -0.57 and a beta of 0.78. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. Werewolf Therapeutics has a one year low of $0.53 and a one year high of $2.38. The business has a 50-day moving average of $0.69 and a 200-day moving average of $1.03.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Friday, March 27th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.14. As a group, equities research analysts anticipate that Werewolf Therapeutics will post -1.56 EPS for the current fiscal year.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.